Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMSQDLE)

Drug Name
Flecainide Drug Info
Synonyms
flecainide; 54143-55-4; Flecaine; Tambocor; Flecainida; Flecainidum; (+-)-Flecainide; Flecainidum [INN-Latin]; Flecainida [INN-Spanish]; N-(piperidin-2-ylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamide; Flecainide [INN:BAN]; CCRIS 313; Benzamide, N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-; C17H20F6N2O3; CHEMBL652; N-(2-Piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamide; CHEBI:75984; DJBNUMBKLMJRSA-UHFFFAOYSA-N; NCGC00015443-06; DSSTox_CID_3054; DSSTox_RID_76854; DSSTox_GSID_23054; (-)-Flecainide; Flecaine; Almarytm (TN); Apocard (TN); Ecrinal (TN); Flecainide (INN); Tambocor (TN); N-(piperidin-2-ylmethyl)-2,5-bis[(2,2,2-trifluoroethyl)oxy]benzamide; Ic Flecainide
Indication
Disease Entry ICD 11 Status REF
Tachyarrhythmias BC71 Approved [1]
Paroxysmal atrial fibrillation BC81.30 Phase 1 [2]
Atrial fibrillation BC81.3 Investigative [3]
Therapeutic Class
Antiarrhythmic Agents
Cross-matching ID
PubChem CID
3356
ChEBI ID
CHEMBL75984
CAS Number
CAS 54143-55-4
TTD Drug ID
DMSQDLE
VARIDT Drug ID
DR00512
INTEDE Drug ID
DR0700
ACDINA Drug ID
D00278

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DME
DOT
Drug Status:
Approved Drug(s)
Discontinued Drug(s)
Clinical Trial Drug(s)
Investigative Drug(s)
Patented Agent(s)
Download the Complete Related Drug List
Drug(s) Targeting E3 ubiquitin-protein ligase COP1 (RFWD2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Quinine DMSWYF5 Malaria 1F40-1F45 Approved [4]
Procainamide DMNMXR8 Ventricular arrhythmias BC71 Approved [4]
Propafenone DMPIBJK Tachyarrhythmias BC71 Approved [4]
Tocainide DMYNMDP Ventricular arrhythmias BC71 Approved [4]
Barucainide DMTMS3L Heart arrhythmia BC65 Terminated [10]
Drug(s) Targeting Voltage-gated sodium channel alpha Nav1.9 (SCN11A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Lidocaine DML4ZOT Anaesthesia 9A78.6 Approved [11]
Lamotrigine DM8SXYG Bipolar disorder 6A60 Approved [12]
Lacosamide DMVM6QR Convulsion 8A68.Z Approved [13]
Riluzole DMECBWN Amyotrophic lateral sclerosis 8B60.0 Approved [14]
Tolperisone DMA2GHJ Muscle spasm MB47.3 Approved [15]
Eslicarbazepine DMZREFQ Seizure disorder 8A6Z Approved [13]
Oxcarbazepine DM5PU6O Epilepsy 8A60-8A68 Approved [16]
HP-184 DMNOMV2 Multiple sclerosis 8A40 Phase 2 [17]
QX-314 DMAV2FM Pain MG30-MG3Z Terminated [18]
PD-32577 DMBA15J Discovery agent N.A. Investigative [19]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Cytochrome P450 1A2 (CYP1A2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Fluorouracil DMUM7HZ Adenocarcinoma 2D40 Approved [20]
Dinoprostone DMTYOPD Medical abortion JA00.1Z Approved [21]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [22]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [23]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [24]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [25]
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [26]
Oxaliplatin DMQNWRD Adenocarcinoma 2D40 Approved [27]
Verapamil DMA7PEW Angina pectoris BA40 Approved [28]
Diclofenac DMPIHLS Chronic renal failure GB61.Z Approved [29]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Cytochrome P450 2D6 (CYP2D6)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [30]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [31]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [32]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [33]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [34]
Quinine DMSWYF5 Malaria 1F40-1F45 Approved [35]
Propofol DMB4OLE Anaesthesia 9A78.6 Approved [36]
Dopamine DMPGUCF Acromegaly 5A60.0 Approved [37]
Nicotine DMWX5CO Lung cancer 2C25.0 Approved [38]
Propranolol DM79NTF Angina pectoris BA40 Approved [39]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Sodium channel protein type 5 subunit alpha (SCN5A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Disopyramide DM5SYZP Long QT syndrome BC65.0 Approved [8]
Amiodarone DMUTEX3 Tachyarrhythmias BC71 Approved [40]
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [41]
Meloxicam DM2AR7L Arthritis FA20 Approved [42]
Quercetin DM3NC4M Obesity 5B81 Approved [43]
Crizotinib DM4F29C Non-small-cell lung cancer 2C25.Y Approved [44]
Nefazodone DM4ZS8M Major depressive disorder 6A70.3 Approved [45]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [46]
Retigabine DMGNYIH Behcet disease 4A62 Approved [47]
Luvox DMJKROX Anxiety disorder 6B00-6B0Z Approved [48]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Nuclear protein 1 (NUPR1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [49]
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [6]
Ofloxacin DM0VQN3 Acute gonococcal cervicitis Approved [7]
Citalopram DM2G9AE Acute coronary syndrome BA41 Approved [50]
Imipramine DM2NUH3 Depression 6A70-6A7Z Approved [6]
Thioridazine DM35M8J Schizophrenia 6A20 Approved [6]
Quercetin DM3NC4M Obesity 5B81 Approved [51]
Fluoxetine DM3PD2C Bipolar depression Approved [6]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [52]
Erythromycin DM4K7GQ Acne vulgaris ED80 Approved [7]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Alpha-1-antichymotrypsin (SERPINA3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [6]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [53]
Citalopram DM2G9AE Acute coronary syndrome BA41 Approved [50]
Imipramine DM2NUH3 Depression 6A70-6A7Z Approved [6]
Thioridazine DM35M8J Schizophrenia 6A20 Approved [6]
Rofecoxib DM3P5DA Osteoarthritis FA00-FA05 Approved [54]
Fluoxetine DM3PD2C Bipolar depression Approved [6]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [55]
Isotretinoin DM4QTBN Acne vulgaris ED80 Approved [55]
Chlorpromazine DMBGZI3 Acute intermittent hepatic porphyria 5C58.11 Approved [6]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Solute carrier family 2, facilitated glucose transporter member 3 (SLC2A3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
2-deoxyglucose DMIAHVU Solid tumour/cancer 2A00-2F9Z Approved [56]
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [57]
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [6]
Citalopram DM2G9AE Acute coronary syndrome BA41 Approved [50]
Imipramine DM2NUH3 Depression 6A70-6A7Z Approved [6]
Methotrexate DM2TEOL Anterior urethra cancer Approved [58]
Thioridazine DM35M8J Schizophrenia 6A20 Approved [6]
Quercetin DM3NC4M Obesity 5B81 Approved [51]
Fluoxetine DM3PD2C Bipolar depression Approved [6]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [59]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Inhibin beta E chain (INHBE)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [6]
Citalopram DM2G9AE Acute coronary syndrome BA41 Approved [50]
Imipramine DM2NUH3 Depression 6A70-6A7Z Approved [6]
Thioridazine DM35M8J Schizophrenia 6A20 Approved [6]
Quercetin DM3NC4M Obesity 5B81 Approved [51]
Fluoxetine DM3PD2C Bipolar depression Approved [6]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [60]
Erythromycin DM4K7GQ Acne vulgaris ED80 Approved [7]
Clarithromycin DM4M1SG Acute maxillary sinusitis Approved [6]
Panobinostat DM58WKG Chronic graft versus host disease Approved [61]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Acid ceramidase (ASAH1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [6]
Beta-carotene DM0RXBT Vitamin deficiency 5B55-5B71 Approved [62]
Ofloxacin DM0VQN3 Acute gonococcal cervicitis Approved [7]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [63]
Imipramine DM2NUH3 Depression 6A70-6A7Z Approved [6]
Thioridazine DM35M8J Schizophrenia 6A20 Approved [7]
Quercetin DM3NC4M Obesity 5B81 Approved [51]
Fluoxetine DM3PD2C Bipolar depression Approved [6]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [64]
Erythromycin DM4K7GQ Acne vulgaris ED80 Approved [7]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Lysophospholipase D GDPD3 (GDPD3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [6]
Citalopram DM2G9AE Acute coronary syndrome BA41 Approved [50]
Imipramine DM2NUH3 Depression 6A70-6A7Z Approved [6]
Thioridazine DM35M8J Schizophrenia 6A20 Approved [7]
Fluoxetine DM3PD2C Bipolar depression Approved [7]
Chlorpromazine DMBGZI3 Acute intermittent hepatic porphyria 5C58.11 Approved [6]
Hydroquinone DM6AVR4 Melasma ED60.1 Approved [65]
Testosterone DM7HUNW Hot flushes GA30 Approved [66]
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [66]
Haloperidol DM96SE0 Delirium Approved [7]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Protein DEPP1 (DEPP1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [6]
Ofloxacin DM0VQN3 Acute gonococcal cervicitis Approved [7]
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [67]
Imipramine DM2NUH3 Depression 6A70-6A7Z Approved [6]
Thioridazine DM35M8J Schizophrenia 6A20 Approved [6]
Quercetin DM3NC4M Obesity 5B81 Approved [51]
Fluoxetine DM3PD2C Bipolar depression Approved [6]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [68]
Erythromycin DM4K7GQ Acne vulgaris ED80 Approved [7]
Isoniazid DM5JVS3 Latent tuberculosis infection Approved [7]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By AP-1 complex subunit sigma-1A (AP1S1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [69]
Thioridazine DM35M8J Schizophrenia 6A20 Approved [6]
Quercetin DM3NC4M Obesity 5B81 Approved [51]
Fluoxetine DM3PD2C Bipolar depression Approved [6]
Chlorpromazine DMBGZI3 Acute intermittent hepatic porphyria 5C58.11 Approved [7]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [70]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [71]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [72]
Ivermectin DMDBX5F Intestinal strongyloidiasis due to nematode parasite 1F6B Approved [73]
Loratadine DMF3AN7 Allergy 4A80-4A85 Approved [50]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Nuclear receptor subfamily 0 group B member 2 (NR0B2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Calcipotriol DM03CP7 Psoriasis EA90 Approved [74]
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [6]
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [75]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [76]
Clavulanate DM2FGRT Bacteremia 1A73 Approved [77]
Imipramine DM2NUH3 Depression 6A70-6A7Z Approved [6]
Thioridazine DM35M8J Schizophrenia 6A20 Approved [7]
Deoxycholic acid DM3GYAL Subcutaneous fat disorder EF02 Approved [78]
Quercetin DM3NC4M Obesity 5B81 Approved [51]
Fluoxetine DM3PD2C Bipolar depression Approved [6]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Fibronectin type III domain-containing protein 4 (FNDC4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [6]
Imipramine DM2NUH3 Depression 6A70-6A7Z Approved [6]
Thioridazine DM35M8J Schizophrenia 6A20 Approved [6]
Fluoxetine DM3PD2C Bipolar depression Approved [6]
Erythromycin DM4K7GQ Acne vulgaris ED80 Approved [7]
Chlorpromazine DMBGZI3 Acute intermittent hepatic porphyria 5C58.11 Approved [6]
Haloperidol DM96SE0 Delirium Approved [7]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [71]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [79]
Clozapine DMFC71L Schizophrenia 6A20 Approved [6]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Protein c-Fos (FOS)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [80]
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [81]
Verapamil DMA7PEW Angina pectoris BA40 Approved [82]
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [83]
Acebutolol DM0TI4U Hypertension BA00-BA04 Approved [82]
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [84]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [85]
Methotrexate DM2TEOL Anterior urethra cancer Approved [86]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [87]
Quercetin DM3NC4M Obesity 5B81 Approved [88]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 (HCN4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [89]
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [90]
Triclosan DMZUR4N Malaria 1F40-1F45 Approved [91]
SNDX-275 DMH7W9X Breast cancer 2C60-2C65 Phase 3 [61]
Benzo(a)pyrene DMN7J43 N. A. N. A. Phase 1 [92]
PMID28460551-Compound-2 DM4DOUB N. A. N. A. Patented [93]
Formaldehyde DM7Q6M0 Discovery agent N.A. Investigative [94]
aconitine DMFOZ60 Discovery agent N.A. Investigative [95]
acetaldehyde DMJFKG4 Discovery agent N.A. Investigative [96]
⏷ Show the Full List of 9 Drug(s)
Drug(s) Affected By Potassium voltage-gated channel subfamily E member 1 (KCNE1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tretinoin DM49DUI Acne vulgaris ED80 Approved [97]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [98]
Pentobarbital DMFNH7L Brain ischaemia 8B1Z Approved [99]
Verapamil DMA7PEW Angina pectoris BA40 Approved [8]
Propranolol DM79NTF Angina pectoris BA40 Approved [8]
Diltiazem DMAI7ZV Angina pectoris BA40 Approved [8]
Sotalol DML60TN Sinus rhythm disorder BC9Y Approved [8]
Quinidine DMLPICK N. A. N. A. Approved [8]
Amiodarone DMUTEX3 Tachyarrhythmias BC71 Approved [8]
Atenolol DMNKG1Z Angina pectoris BA40 Approved [8]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
E3 ubiquitin-protein ligase COP1 (RFWD2) TT05DLS COP1_HUMAN Modulator [4]
Voltage-gated sodium channel (Nav) TTIG65Q NOUNIPROTAC Modulator [4]
Voltage-gated sodium channel alpha Nav1.9 (SCN11A) TTN9VTF SCNBA_HUMAN Blocker [3]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 2D6 (CYP2D6) Main DME DECB0K3 CP2D6_HUMAN Substrate [5]
Cytochrome P450 1A2 (CYP1A2) Main DME DEJGDUW CP1A2_HUMAN Substrate [5]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Acid ceramidase (ASAH1) OT1DNGXL ASAH1_HUMAN Gene/Protein Processing [6]
Alpha-1-antichymotrypsin (SERPINA3) OT9BP2S0 AACT_HUMAN Gene/Protein Processing [6]
AP-1 complex subunit sigma-1A (AP1S1) OTQ2H8DN AP1S1_HUMAN Gene/Protein Processing [7]
Fibronectin type III domain-containing protein 4 (FNDC4) OTOQK0WK FNDC4_HUMAN Gene/Protein Processing [7]
Inhibin beta E chain (INHBE) OTOI2NYG INHBE_HUMAN Gene/Protein Processing [6]
Lysophospholipase D GDPD3 (GDPD3) OTOHM9QM GDPD3_HUMAN Gene/Protein Processing [6]
Nuclear protein 1 (NUPR1) OT4FU8C0 NUPR1_HUMAN Gene/Protein Processing [6]
Nuclear receptor subfamily 0 group B member 2 (NR0B2) OT7UVICX NR0B2_HUMAN Gene/Protein Processing [7]
Potassium voltage-gated channel subfamily E member 1 (KCNE1) OTZNQUW9 KCNE1_HUMAN Drug Response [8]
Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 (HCN4) OTPH3RRX HCN4_HUMAN Gene/Protein Processing [9]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2560).
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 New antiarrhythmic agents for atrial fibrillation and atrial flutter. Expert Opin Emerg Drugs. 2005 May;10(2):311-22.
4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
5 Flecainide: current status and perspectives in arrhythmia management. World J Cardiol. 2015 Feb 26;7(2):76-85.
6 A toxicogenomic approach to drug-induced phospholipidosis: analysis of its induction mechanism and establishment of a novel in vitro screening system. Toxicol Sci. 2005 Feb;83(2):282-92.
7 Determination of phospholipidosis potential based on gene expression analysis in HepG2 cells. Toxicol Sci. 2007 Mar;96(1):101-14.
8 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
9 Effects of antiarrhythmic drugs on the hyperpolarization-activated cyclic nucleotide-gated channel current. J Pharmacol Sci. 2009 Jun;110(2):150-9. doi: 10.1254/jphs.08312fp. Epub 2009 Jun 5.
10 Barucainide, a novel class Ib antiarrhythmic agent with a slow kinetic property: electrophysiologic observations in isolated canine and rabbit cardiac muscle. Am Heart J. 1990 May;119(5):1050-60.
11 Mechanisms of analgesia of intravenous lidocaine. Rev Bras Anestesiol. 2008 May-Jun;58(3):280-6.
12 The effects of lamotrigine on the acquisition and expression of morphine-induced place preference in mice. Pak J Biol Sci. 2009 Jan 1;12(1):33-9.
13 Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
14 Secondary injury mechanisms of spinal cord trauma: a novel therapeutic approach for the management of secondary pathophysiology with the sodium channel blocker riluzole. Prog Brain Res. 2002;137:177-90.
15 Tolperisone-type drugs inhibit spinal reflexes via blockade of voltage-gated sodium and calcium channels. J Pharmacol Exp Ther. 2005 Dec;315(3):1237-46.
16 Debate: Does genetic information in humans help us treat patients PRO--genetic information in humans helps us treat patients. CON--genetic information does not help at all. Epilepsia. 2008 Dec;49 Suppl 9:13-24.
17 Emerging drugs for spinal cord injury. Expert Opin Emerg Drugs. 2008 Mar;13(1):63-80.
18 Voltage-gated sodium channel blockers for the treatment of chronic pain. Curr Top Med Chem. 2009;9(4):362-76.
19 Synthesis and biological activity of substituted bis-(4-hydroxyphenyl)methanes as N-type calcium channel blockers. Bioorg Med Chem Lett. 1999 Aug 16;9(16):2447-52.
20 Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
21 Effects of polyunsaturated fatty acids on prostaglandin synthesis and cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines in human adenocarcinoma colon cells. Mol Carcinog. 2004 Jul;40(3):180-8.
22 Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab Dispos. 2014 Nov;42(11):1843-50.
23 Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res. 2004;6(4):R352-65.
24 PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 2015 Aug;25(8):416-26.
25 The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int. 2013;2013:789184.
26 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
27 The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
28 Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):332-7.
29 Metabolism and metabolic inhibition of xanthotoxol in human liver microsomes. Evid Based Complement Alternat Med. 2016;2016:5416509.
30 Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
31 Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
32 CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
33 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
34 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
35 Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
36 Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
37 Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
38 Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
39 Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
40 Ethnic-Related Sodium Voltage-Gated Channel Subunit 5 Polymorphisms Shape the In Vitro Pharmacological Action of Amiodarone upon Na(v)1.5. Mol Pharmacol. 2021 Jun;99(6):448-459. doi: 10.1124/molpharm.120.000176. Epub 2021 Apr 6.
41 Inhibitory effects of cannabidiol on voltage-dependent sodium currents. J Biol Chem. 2018 Oct 26;293(43):16546-16558. doi: 10.1074/jbc.RA118.004929. Epub 2018 Sep 14.
42 Regulatory effects of non-steroidal anti-inflammatory drugs on cardiac ion channels Nav1.5 and Kv11.1. Chem Biol Interact. 2021 Apr 1;338:109425. doi: 10.1016/j.cbi.2021.109425. Epub 2021 Feb 19.
43 Quantitative proteomic analysis of HepG2 cells treated with quercetin suggests IQGAP1 involved in quercetin-induced regulation of cell proliferation and migration. OMICS. 2009 Apr;13(2):93-103. doi: 10.1089/omi.2008.0075.
44 Multi-parameter in vitro toxicity testing of crizotinib, sunitinib, erlotinib, and nilotinib in human cardiomyocytes. Toxicol Appl Pharmacol. 2013 Oct 1;272(1):245-55.
45 Evaluation of nefazodone-induced cardiotoxicity in human induced pluripotent stem cell-derived cardiomyocytes. Toxicol Appl Pharmacol. 2016 Apr 1;296:42-53. doi: 10.1016/j.taap.2016.01.015. Epub 2016 Jan 25.
46 Gene Expression Regulation and Pathway Analysis After Valproic Acid and Carbamazepine Exposure in a Human Embryonic Stem Cell-Based Neurodevelopmental Toxicity Assay. Toxicol Sci. 2015 Aug;146(2):311-20. doi: 10.1093/toxsci/kfv094. Epub 2015 May 15.
47 Modulation of the heart's electrical properties by the anticonvulsant drug retigabine. Toxicol Appl Pharmacol. 2017 Aug 15;329:309-317. doi: 10.1016/j.taap.2017.06.018. Epub 2017 Jun 20.
48 Brugada syndrome ECG provoked by the selective serotonin reuptake inhibitor fluvoxamine. Europace. 2010 Feb;12(2):282-3. doi: 10.1093/europace/eup332. Epub 2009 Oct 29.
49 Cannabidiol enhances cytotoxicity of anti-cancer drugs in human head and neck squamous cell carcinoma. Sci Rep. 2020 Nov 26;10(1):20622. doi: 10.1038/s41598-020-77674-y.
50 In vitro detection of drug-induced phospholipidosis using gene expression and fluorescent phospholipid based methodologies. Toxicol Sci. 2007 Sep;99(1):162-73.
51 Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
52 Effect of retinoic acid on gene expression in human conjunctival epithelium: secretory phospholipase A2 mediates retinoic acid induction of MUC16. Invest Ophthalmol Vis Sci. 2005 Nov;46(11):4050-61.
53 Oxidative Stress Alters miRNA and Gene Expression Profiles in Villous First Trimester Trophoblasts. Biomed Res Int. 2015;2015:257090. doi: 10.1155/2015/257090. Epub 2015 Aug 3.
54 Rofecoxib modulates multiple gene expression pathways in a clinical model of acute inflammatory pain. Pain. 2007 Mar;128(1-2):136-47.
55 Retinoic acid and its 4-oxo metabolites are functionally active in human skin cells in vitro. J Invest Dermatol. 2005 Jul;125(1):143-53.
56 Kinetic analysis of the liver-type (GLUT2) and brain-type (GLUT3) glucose transporters in Xenopus oocytes: substrate specificities and effects of transport inhibitors. Biochem J. 1993 Mar 15;290 ( Pt 3)(Pt 3):701-6. doi: 10.1042/bj2900701.
57 Cannabidiol induces antioxidant pathways in keratinocytes by targeting BACH1. Redox Biol. 2020 Jan;28:101321. doi: 10.1016/j.redox.2019.101321. Epub 2019 Sep 5.
58 Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium. Arthritis Rheumatol. 2014 Jan;66(1):15-23.
59 Retinoic acid represses a cassette of candidate pluripotency chromosome 12p genes during induced loss of human embryonal carcinoma tumorigenicity. Biochim Biophys Acta. 2005 Oct 15;1731(1):48-56. doi: 10.1016/j.bbaexp.2005.08.006. Epub 2005 Sep 1.
60 Transcriptomic analysis of untreated and drug-treated differentiated HepaRG cells over a 2-week period. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):27-35.
61 A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
62 Beta-carotene and apocarotenals promote retinoid signaling in BEAS-2B human bronchioepithelial cells. Arch Biochem Biophys. 2006 Nov 1;455(1):48-60.
63 MS4A3-HSP27 target pathway reveals potential for haematopoietic disorder treatment in alimentary toxic aleukia. Cell Biol Toxicol. 2023 Feb;39(1):201-216. doi: 10.1007/s10565-021-09639-4. Epub 2021 Sep 28.
64 Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
65 Keratinocyte-derived IL-36gama plays a role in hydroquinone-induced chemical leukoderma through inhibition of melanogenesis in human epidermal melanocytes. Arch Toxicol. 2019 Aug;93(8):2307-2320.
66 Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
67 ERE-independent ERalpha target genes differentially expressed in human breast tumors. Mol Cell Endocrinol. 2005 Dec 21;245(1-2):53-9. doi: 10.1016/j.mce.2005.10.003. Epub 2005 Nov 17.
68 Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
69 Minimal peroxide exposure of neuronal cells induces multifaceted adaptive responses. PLoS One. 2010 Dec 17;5(12):e14352. doi: 10.1371/journal.pone.0014352.
70 An approach to elucidate potential mechanism of renal toxicity of arsenic trioxide. Exp Hematol. 2007 Feb;35(2):252-62.
71 Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
72 Stem cell transcriptome responses and corresponding biomarkers that indicate the transition from adaptive responses to cytotoxicity. Chem Res Toxicol. 2017 Apr 17;30(4):905-922.
73 Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
74 Adaptive homeostasis of the vitamin D-vitamin D nuclear receptor axis in 8-methoxypsoralen-induced hepatotoxicity. Toxicol Appl Pharmacol. 2019 Jan 1;362:150-158. doi: 10.1016/j.taap.2018.11.002. Epub 2018 Nov 10.
75 Arsenite and cadmium promote the development of mammary tumors. Carcinogenesis. 2020 Jul 14;41(7):1005-1014. doi: 10.1093/carcin/bgz176.
76 Time series analysis of oxidative stress response patterns in HepG2: a toxicogenomics approach. Toxicology. 2013 Apr 5;306:24-34.
77 Molecular mechanisms of hepatotoxic cholestasis by clavulanic acid: Role of NRF2 and FXR pathways. Food Chem Toxicol. 2021 Dec;158:112664. doi: 10.1016/j.fct.2021.112664. Epub 2021 Nov 9.
78 Farnesoid X receptor induces murine scavenger receptor Class B type I via intron binding. PLoS One. 2012;7(4):e35895. doi: 10.1371/journal.pone.0035895. Epub 2012 Apr 23.
79 Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
80 Essential role of cell cycle regulatory genes p21 and p27 expression in inhibition of breast cancer cells by arsenic trioxide. Med Oncol. 2011 Dec;28(4):1225-54.
81 Cannabidiol Activates Neuronal Precursor Genes in Human Gingival Mesenchymal Stromal Cells. J Cell Biochem. 2017 Jun;118(6):1531-1546. doi: 10.1002/jcb.25815. Epub 2016 Dec 29.
82 Selection of drugs to test the specificity of the Tg.AC assay by screening for induction of the gadd153 promoter in vitro. Toxicol Sci. 2003 Aug;74(2):260-70. doi: 10.1093/toxsci/kfg113. Epub 2003 May 2.
83 Sertraline induces endoplasmic reticulum stress in hepatic cells. Toxicology. 2014 Aug 1;322:78-88. doi: 10.1016/j.tox.2014.05.007. Epub 2014 May 24.
84 Estrogen regulation in human breast cancer cells of new downstream gene targets involved in estrogen metabolism, cell proliferation and cell transformation. J Mol Endocrinol. 2004 Apr;32(2):397-414.
85 Microarray analysis of H2O2-, HNE-, or tBH-treated ARPE-19 cells. Free Radic Biol Med. 2002 Nov 15;33(10):1419-32.
86 Methotrexate induces production of IL-1 and IL-6 in the monocytic cell line U937. Arthritis Res Ther. 2014 Jan 20;16(1):R17. doi: 10.1186/ar4444.
87 Simvastatin inhibits NOR-1 expression induced by hyperlipemia by interfering with CREB activation. Cardiovasc Res. 2005 Aug 1;67(2):333-41. doi: 10.1016/j.cardiores.2005.03.016. Epub 2005 Apr 21.
88 The G protein-coupled receptor GPR30 mediates c-fos up-regulation by 17beta-estradiol and phytoestrogens in breast cancer cells. J Biol Chem. 2004 Jun 25;279(26):27008-16. doi: 10.1074/jbc.M403588200. Epub 2004 Apr 16.
89 Multiple microRNAs function as self-protective modules in acetaminophen-induced hepatotoxicity in humans. Arch Toxicol. 2018 Feb;92(2):845-858.
90 Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
91 Transcriptome and DNA methylome dynamics during triclosan-induced cardiomyocyte differentiation toxicity. Stem Cells Int. 2018 Oct 29;2018:8608327.
92 Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
93 Cell-based two-dimensional morphological assessment system to predict cancer drug-induced cardiotoxicity using human induced pluripotent stem cell-derived cardiomyocytes. Toxicol Appl Pharmacol. 2019 Nov 15;383:114761. doi: 10.1016/j.taap.2019.114761. Epub 2019 Sep 15.
94 Cellular reactions to long-term volatile organic compound (VOC) exposures. Sci Rep. 2016 Dec 1;6:37842. doi: 10.1038/srep37842.
95 Notch1-mediated histone demethylation of HCN4 contributes to aconitine-induced ventricular myocardial dysrhythmia. Toxicol Lett. 2020 Jul 1;327:19-31. doi: 10.1016/j.toxlet.2020.03.017. Epub 2020 Mar 28.
96 Transcriptome profile analysis of saturated aliphatic aldehydes reveals carbon number-specific molecules involved in pulmonary toxicity. Chem Res Toxicol. 2014 Aug 18;27(8):1362-70.
97 Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
98 Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
99 Inhibition of cardiac potassium currents by pentobarbital. Naunyn Schmiedebergs Arch Pharmacol. 2002 Jan;365(1):29-37. doi: 10.1007/s00210-001-0490-1. Epub 2001 Nov 8.